You are here: AU  Staff Departments  iNANO News and events News Show

NNF, Hallas-Møller Ascending Investigator

2019.01.09 | Yvonne Eskildsen-Helmond

The Novo Nordisk Foundation - Hallas-Møller Ascending Investigator

Deadline: January 9, 2019


To stimulate the continued development of excellent research leaders, and promote Danish fundamental research at a high international level, the Novo Nordisk Foundation seeks to support the consolidation of accomplished associate professors with ambitious projects relevant to understanding the human organism and/or basal mechanisms underlying health and disease.

The Ascending Investigator grant is for excellent and independent associate professors who have the ambition and potential to rise to the highest international level within their research fields. Applicants should have their own research group and individual research profile and are expected to have a documented track record of peer-reviewed research with a high impact, and must at the time of application have senior authorships. Ideally, after their PhD degree, applicants should have approximately 7-15 years of subsequent research experience (parental leave excluded).



  • Applicants should be associate professors. Applications from assistant professors, senior researchers or people in similar research positions will be considered if the application meet all the other requirements in this call. Professors, including MSO, cannot apply for this particular call – but can apply for Novo Nordisk Foundation’s Distinguished Investigator grant.
  • During the project, applicants must be primarily employed, and have their primary research group, in Denmark.
  • The project must be anchored at a university, hospital or other non-profit research institution in Denmark.
  • Recipients of this grant must contribute to the pre-graduate teaching environment at their host institution. An Ascending Investigator grant must not be used to cover a teaching substitute for the applicant.

Read more here

Funding opportunities
Tags: Novo Nordisk, Biomedical Research
4871 / i35